EGFR MUTATED NON-SMALL CELL LUNG CANCER PATIENTS

Clinical trials for EGFR MUTATED NON-SMALL CELL LUNG CANCER PATIENTS explained in plain language.

Never miss a new study

Get alerted when new EGFR MUTATED NON-SMALL CELL LUNG CANCER PATIENTS trials appear

Sign up with your email to follow new studies for EGFR MUTATED NON-SMALL CELL LUNG CANCER PATIENTS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 1

New hope for lung cancer patients who stopped responding to standard treatment

Disease control Recruiting now

This early-stage study is testing whether adding an experimental drug called NXP900 to a standard lung cancer medication (osimertinib) can help control advanced lung cancer that has started growing again. The trial will enroll about 18 adults whose cancer has a specific genetic c…

Matched conditions: EGFR MUTATED NON-SMALL CELL LUNG CANCER PATIENTS

Phase: PHASE1 • Sponsor: Nuvectis Pharma, Inc. • Aim: Disease control

Last updated Mar 20, 2026 14:48 UTC

EGFR MUTATED NON-SMALL CELL LUNG CANCER PATIENTS

Get alerted when new EGFR MUTATED NON-SMALL CELL LUNG CANCER PATIENTS trials appear

New hope for lung cancer patients who stopped responding to standard treatment